The American Food and Drug Administration has approved a new type 2 diabetes drug to be used in conjunction with metformin, sulfonylureas or insulin .
Welchol, manufactured by Daiichi Sankyo Inc. is the first medication that is approved to reduce both glucose levels and LDL cholesterol levels. Some 40 per cent of type 2 diabetics also suffer from high levels of LDL, so Welchol treats both chronic conditions simultaneously.
Clinically proven data indicates that Welchol could lower haemoglobin A1c and LDL levels amongst patients struggling to control their condition with metformin.
Ronald Goldberg MD, professor of medicine in the division of diabetes and metabolism at the University of Miami Miller School of Medicine was reported as commenting:
“Cardiovascular risk factors are of great concern because patients with type 2 diabetes have a significantly increased risk of developing cardiovascular disease .”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…